Adalimumab effect on COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20171105037262N4
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Having COVID-19
Respiratory distress with over 30 breaths per minute
O2 saturation less than 93% at rest
PaO2/Fio2 less than 300 mmHg
HRCT indicating COVID-19
positive PCR test result
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease severity. Timepoint: At the beginning and end of the intervention. Method of measurement: According to protocol and clinical symptoms.
- Secondary Outcome Measures
Name Time Method